Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 3/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403906 | 0.78 | CES2 (0.41) | HSD17B10LMNACYP17A1CYP3A4CYP11B1 | |
| SCHEMBL3316934 | 0.78 | PTGS2 (0.48) | HSD17B10LMNAKDM4EALDH1A1HTT | |
| SCHEMBL12228262 | 0.74 | MAPT (0.40) | HSD17B10LMNAKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL1274361 | 0.74 | ALDH1A1 (0.34) | HSD17B10LMNACYP3A4ALDH1A1HTT | |
| SCHEMBL29577999 | 0.74 | ALDH1A1 (0.34) | HSD17B10LMNACYP3A4ALDH1A1HTT | |
| SCHEMBL4845445 | 0.74 | TDP1 (0.49) | KDM4EESR1ESR2ALDH1A1HTT | |
| SCHEMBL25453075 | 0.73 | KDM1A (0.37) | HSD17B10LMNAKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL639211 | 0.73 | RAB9A (0.52) | HSD17B10KDM4EHSD17B1ESR1ESR2 | |
| SCHEMBL11213671 | 0.73 | PTGS1 (0.53) | HSD17B10LMNAESR1ESR2CYP3A4 | |
| SCHEMBL18403872 | 0.73 | ALOX15 (0.50) | HSD17B10LMNAALDH1A1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100402487-C | Method for preparing 2-fluoro-4-nitrophenol | CHANGZHOU YETAI FINE CHEMICAL (CN) | 2008-07-16 | — | — | CN | claimed |
| CN-1850778-A | Method for preparing 2-fluoro-4-nitrophenol | YETAI FINE CHEMICAL INST CHANG (CN) | 2006-10-25 | — | — | CN | claimed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| CN-100402487-C | Method for preparing 2-fluoro-4-nitrophenol | CHANGZHOU YETAI FINE CHEMICAL (CN) | 2008-07-16 | — | — | CN | disclosed |
| CN-100402487-C | Method for preparing 2-fluoro-4-nitrophenol | CHANGZHOU YETAI FINE CHEMICAL (CN) | 2008-07-16 | — | — | CN | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| CN-1850778-A | Method for preparing 2-fluoro-4-nitrophenol | YETAI FINE CHEMICAL INST CHANG (CN) | 2006-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | HSD17B10 2594/4885LMNA 3109/4885KDM4E 776/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | HSD17B10 892/4885LMNA 4840/4885KDM4E 4651/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | HSD17B10 2594/4885LMNA 3109/4885KDM4E 776/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | HSD17B10 3782/4885LMNA 4752/4885KDM4E 2282/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | HSD17B10 1083/4885LMNA 3284/4885KDM4E 1111/4885 |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | HSD17B10 922/4885LMNA 3752/4885KDM4E 3651/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | HSD17B10 3782/4885LMNA 4752/4885KDM4E 2282/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | HSD17B10 686/4885LMNA 3964/4885KDM4E 3048/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | HSD17B10 3782/4885LMNA 4752/4885KDM4E 2282/4885 |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ABL1, ERBB2, TYRO3 | HSD17B10 4206/4885LMNA 4639/4885KDM4E 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.